Erin Verity
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Erin Verity has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Anthony Lawrence Cunningham
The Westmead Institute for Medical Research, University of Sydney, Sydney, Australia
1 shared publication - Bruce James Brew
Peter Duncan Neuroscience Research Unit, St. Vincent's Centre for Applied Medical Research, Sydney, New South Wales, Australia
1 shared publication - Dale A. McPhee
National Serology Reference Laboratory, Melbourne, Victoria, Australia
1 shared publication - Dana Gabuzda
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
1 shared publication - Jennifer C. Learmont
Australian Red Cross Blood Service, Sydney, New South Wales, Australia
1 shared publication - John Mills
Department of Medicine, Monash University, Melbourne, Victoria, Australia
1 shared publication
Latest Publications
- Open Access
- 1 January 2007
- Published by Springer Nature in Retrovirology
- Vol. 4 (1) , 66
Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo
In efforts to develop an effective vaccine, sterilizing immunity to primate lentiviruses has only been achieved by the use of live attenuated viruses carrying major deletions in nef and other accessory genes. Although live attenuated HIV vaccines are unlikely to be developed due to a myriad of safety concerns, opportunities exist to better understand the correlates of immune protection against HIV infection by studying rare cohorts of long-term survivors infected with attenuated, nef-deleted HIV strains such as the Sydney blood bank cohort (SBBC). Here, we review studies of viral evolution, pathogenicity, and immune responses to HIV infection in SBBC members. The studies show that potent, broadly neutralizing anti-HIV antibodies and robust CD8+ T-cell responses to HIV infection were not necessary for long-term control of HIV infection in a subset of SBBC members, and were not sufficient to prevent HIV sequence evolution, augmentation of pathogenicity and eventual progression of HIV infection in another subset. However, a persistent T-helper proliferative response to HIV p24 antigen was associated with long-term control of infection. Together, these results underscore the importance of the host in the eventual outcome of infection. Thus, whilst generating an effective antibody and CD8+ T-cell response are an essential component of vaccines aimed at preventing primary HIV infection, T-helper responses may be important in the generation of an effective therapeutic vaccine aimed at blunting chronic HIV infection.
- 1 January 2007
- Published by Springer Nature in Retrovirology
- Vol. 4 (1) , 66
Open AccessPathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo
In efforts to develop an effective vaccine, sterilizing immunity to primate lentiviruses has only been achieved by the use of live attenuated viruses carrying major deletions in nef and other accessory genes. Although live attenuated HIV vaccines are unlikely to be developed due to a myriad of safety concerns, opportunities exist to better understand the correlates of immune protection against HIV infection by studying rare cohorts of long-term survivors infected with attenuated, nef-deleted HIV strains such as the Sydney blood bank cohort (SBBC). Here, we review studies of viral evolution, pathogenicity, and immune responses to HIV infection in SBBC members. The studies show that potent, broadly neutralizing anti-HIV antibodies and robust CD8+ T-cell responses to HIV infection were not necessary for long-term control of HIV infection in a subset of SBBC members, and were not sufficient to prevent HIV sequence evolution, augmentation of pathogenicity and eventual progression of HIV infection in another subset. However, a persistent T-helper proliferative response to HIV p24 antigen was associated with long-term control of infection. Together, these results underscore the importance of the host in the eventual outcome of infection. Thus, whilst generating an effective antibody and CD8+ T-cell response are an essential component of vaccines aimed at preventing primary HIV infection, T-helper responses may be important in the generation of an effective therapeutic vaccine aimed at blunting chronic HIV infection.